drugset / Trial / NCT01912261
Effects of Oral Iron on Postoperative Fatigue Upon Coronary Artery Bypass Graft Patients
Phase 3
Terminated
121 enrolled
Nova Scotia Health Authority
Capital Health, Canada · collabDalhousie University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this research study is to examine how an oral iron supplement (Feramax®) influences fatigue during early postoperative recovery (at three months) among CABG patients and, the effects on recovery outcomes (e.g. quality of life, functional capacity, anemia, and medication adherence). It is hypothesized that CABG surgery patients receiving oral iron (Feramax®) 150mg orally (once a day therapy) will have a 15% reduction in POF (measured by the Identity Consequence Fatigue Scale (ICFS)), compared to patients receiving a placebo.
Timeline
- Start
- 2014-12-16
- Primary completion
- 2018-02-21
- Completion
- 2019-02
Outcome
Outcome not reported
Stopped: “The study was stopped due to time constraints and resources”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Polysaccharide iron complex | Unknown | 150 mg | Oral |
Indications
No indication recorded.